Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab cognitive function study (EBBINGHAUS)
NCT02207634Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2014
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia comparing Evolocumab with Placebo (2 arms). Primary endpoint: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score at 19.4 months. Started Sep 2014; status: completed.
02
Drugs
evolocumab
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02207634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207634.